TNFRSF10B and cancer: Although the correlation between the basal expression levels of the functional death receptors, DR4 or DR5, and the sensitivity of cancer cells to TRAIL treatment has not been demonstrated [27, 36, 37], our results are consistent with previous observations that upregulation of DR4 and DR5 enhance TRAIL-induced apoptosis in a variety of cancers [38–40].